Unknown PHASE3 INTERVENTIONAL NCT00005871

Nitrocamptothecin or Fluorouracil in Treating Patients With Recurrent or Refractory Pancreatic Cancer

Phase III Randomized Study of RFS 2000 (9-Nitro-Camptothecin, 9-NC) Versus 5-Fluorouracil (5-FU) in Pancreatic Cancer Patients That Have Progressive Disease Following Gemcitabine HCl Treatment

Sponsor: Astex Pharmaceuticals, Inc.

Conditions Pancreatic Cancer

Interventions fluorouracil rubitecan

Updated 6 times since 2017 Last updated: Dec 3, 2013 Started: Nov 30, 1998

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Pancreatic Cancer and is currently ongoing. Astex Pharmaceuticals, Inc. leads this study, which shows 6 recorded versions since 1998 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE3

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE3
Feb 2020 — Jan 2021 [monthly]

Unknown Status PHASE3
Jun 2018 — Feb 2020 [monthly]

Unknown Status PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE3

First recorded

Nov 1998

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Astex Pharmaceuticals, Inc.

Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• San Ramon, United States